Lineage Cell Therapeutics (LCTX) Projected to Post Quarterly Earnings on Thursday

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) will likely be posting its Q4 2025 results after the market closes on Thursday, March 5th. Analysts expect the company to announce earnings of ($0.07) per share and revenue of $1.96 million for the quarter. Investors may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, March 5, 2026 at 4:30 PM ET.

Lineage Cell Therapeutics Trading Down 3.1%

Shares of NYSEAMERICAN LCTX opened at $1.89 on Wednesday. The company’s 50-day moving average price is $1.71 and its 200 day moving average price is $1.64. Lineage Cell Therapeutics has a 52 week low of $0.37 and a 52 week high of $2.09. The stock has a market cap of $435.32 million, a price-to-earnings ratio of -6.52 and a beta of 1.74.

Hedge Funds Weigh In On Lineage Cell Therapeutics

Several large investors have recently bought and sold shares of the stock. XTX Topco Ltd acquired a new stake in shares of Lineage Cell Therapeutics in the 4th quarter worth approximately $71,000. Jain Global LLC raised its holdings in Lineage Cell Therapeutics by 202.3% during the fourth quarter. Jain Global LLC now owns 38,851 shares of the company’s stock worth $65,000 after purchasing an additional 26,000 shares in the last quarter. ExodusPoint Capital Management LP bought a new stake in Lineage Cell Therapeutics during the fourth quarter worth approximately $303,000. Squarepoint Ops LLC acquired a new stake in Lineage Cell Therapeutics in the fourth quarter worth approximately $109,000. Finally, OMERS ADMINISTRATION Corp bought a new position in Lineage Cell Therapeutics during the 4th quarter valued at $473,000. Institutional investors and hedge funds own 62.47% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently commented on LCTX. D. Boral Capital reiterated a “buy” rating and issued a $2.00 price target on shares of Lineage Cell Therapeutics in a research report on Monday, February 9th. HC Wainwright reaffirmed a “buy” rating and issued a $9.00 target price on shares of Lineage Cell Therapeutics in a research note on Monday, November 24th. Three equities research analysts have rated the stock with a Buy rating, According to MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $4.67.

About Lineage Cell Therapeutics

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel, allogeneic cell therapies built on pluripotent stem cell platforms. The company focuses on three primary therapeutic areas—retinal disease, neural repair and immune-effector cell oncology—leveraging its proprietary manufacturing processes to create off-the-shelf cell therapy candidates designed for broad patient populations.

Its lead candidate, OpRegen, comprises retinal pigment epithelium cells intended to slow or reverse vision loss in patients with geographic atrophy secondary to age-related macular degeneration.